Brand/Generic Settlements Not Necessarily Illegal, DoJ Tells Supreme Court
Executive Summary
Payments to generic companies to settle patent challenges under the Hatch-Waxman Act are not necessarily violations of antitrust law, the Office of the Solicitor General says in an amicus curiae brief to the U.S. Supreme Court
You may also be interested in...
Brand/Generic Settlements May Get Supreme Court Review In Tamoxifen Case
The U.S. Supreme Court may take up the question of whether reverse settlements between brand and generic companies can violate antitrust laws
Brand/Generic Settlements May Get Supreme Court Review In Tamoxifen Case
The U.S. Supreme Court may take up the question of whether reverse settlements between brand and generic companies can violate antitrust laws
FTC Commissioner Urges Generic Firms To Shun Reverse Payment Deals
The generic industry should refrain from entering into settlement agreements with brand companies that involve payments to keep generics off the market, Federal Trade Commissioner Jon Leibowitz said at the Generic Pharmaceutical Association's Annual Policy Conference in Washington, D.C. Sept. 19